What is the projected market valuation of the Infectious Disease Diagnosis Treatment Market by 2035?

The market is projected to reach a valuation of 151.26 USD Billion by 2035. Read More

What was the overall market valuation of the Infectious Disease Diagnosis Treatment Market in 2024?

In 2024, the overall market valuation was 113.81 USD Billion. Read More

What is the expected CAGR for the Infectious Disease Diagnosis Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 2.62%. Read More

Which segment of the market is projected to have the highest valuation by 2035?

Molecular Diagnostics is projected to reach a valuation of 60.0 USD Billion by 2035. Read More

What are the projected valuations for antibiotics in the treatment segment by 2035?

Antibiotics are projected to reach a valuation of 54.0 USD Billion by 2035. Read More

Which key players are leading the Infectious Disease Diagnosis Treatment Market?

Key players include Abbott Laboratories, Roche Holding AG, and Thermo Fisher Scientific Inc. Read More

What is the projected valuation for viral infections in the market by 2035?

Viral infections are projected to reach a valuation of 50.0 USD Billion by 2035. Read More

How does the valuation of rapid diagnostic tests compare to serological tests by 2035?

Rapid diagnostic tests are projected to reach 30.0 USD Billion, while serological tests are expected to reach 40.0 USD Billion by 2035. Read More

What is the expected valuation for home care settings in the market by 2035?

Home care settings are projected to reach a valuation of 30.0 USD Billion by 2035. Read More

What is the projected valuation for antifungals in the treatment segment by 2035?

Antifungals are projected to reach a valuation of 22.26 USD Billion by 2035. Read More

Infectious Disease Diagnosis & Treatment Market

ID: MRFR/Pharma/5566-HCR

90 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Infectious Disease Diagnosis Treatment Market Research Report: Size, Share, Trend Analysis By Diagnosis Method (Molecular Diagnostics, Serological Tests, Rapid Diagnostic Tests, Culture Methods), By Treatment Type (Antibiotics, Antivirals, Vaccines, Antifungals), By Infectious Disease Type (Bacterial Infections, Viral Infections, Fungal Infections, Parasitic Infections), By End Users (Hospitals, Clinical Laboratories, Home Care Settings, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Infectious Disease Diagnosis & Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)2.62%

2024 Market Size$ 113.81 Billion

2025 Market Size$ 116.79 Billion

2035 Market Size$ 151.26 Billion

Key Players

Abbott Laboratories

Roche Holding AG

Thermo Fisher Scientific Inc.

Siemens Healthineers

BD (Becton

Dickinson and Company)

Trends

Technological Advancements in Diagnostics
Rise of Telemedicine
Focus on Personalized Medicine

Opportunities

Government Initiatives and Funding
Emergence of Antimicrobial Resistance
Advancements in Diagnostic Technologies

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Diagnosis Method (USD Billion) | |
  1. 4.1.1 Molecular Diagnostics | |
  2. 4.1.2 Serological Tests | |
  3. 4.1.3 Rapid Diagnostic Tests | |
  4. 4.1.4 Culture Methods |
2. 4.2 Healthcare, BY Treatment Type (USD Billion) | |
  1. 4.2.1 Antibiotics | |
  2. 4.2.2 Antivirals | |
  3. 4.2.3 Vaccines | |
  4. 4.2.4 Antifungals |
3. 4.3 Healthcare, BY Infectious Disease Type (USD Billion) | |
  1. 4.3.1 Bacterial Infections | |
  2. 4.3.2 Viral Infections | |
  3. 4.3.3 Fungal Infections | |
  4. 4.3.4 Parasitic Infections |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinical Laboratories | |
  3. 4.4.3 Home Care Settings | |
  4. 4.4.4 Research Institutes |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Abbott Laboratories (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche Holding AG (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Thermo Fisher Scientific Inc. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Siemens Healthineers (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 BD (Becton, Dickinson and Company) (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 bioMerieux SA (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Cepheid (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Hologic Inc. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 QuidelOrtho Corporation (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD |
7. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE |
8. 6.5 US MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD |
11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY END USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD |
16. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
19. 6.16 UK MARKET ANALYSIS BY DIAGNOSIS METHOD |
20. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE |
21. 6.18 UK MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
22. 6.19 UK MARKET ANALYSIS BY END USER |
23. 6.20 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD |
24. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
28. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
31. 6.28 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD |
32. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
34. 6.31 ITALY MARKET ANALYSIS BY END USER |
35. 6.32 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD |
36. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
45. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
47. 6.44 CHINA MARKET ANALYSIS BY END USER |
48. 6.45 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
49. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
51. 6.48 INDIA MARKET ANALYSIS BY END USER |
52. 6.49 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD |
53. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
61. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
64. 6.61 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD |
65. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
69. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD |
73. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD |
78. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
81. 6.78 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD |
82. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
86. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD |
103. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY INFECTIOUS DISEASE TYPE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY INFECTIOUS DISEASE TYPE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY INFECTIOUS DISEASE TYPE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY INFECTIOUS DISEASE TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Infectious Disease Diagnosis & Treatment Market Segmentation

Infectious Disease Diagnosis & Treatment Market By Diagnosis Method (USD Billion, 2025-2035)

Molecular Diagnostics
Serological Tests
Rapid Diagnostic Tests
Culture Methods

Infectious Disease Diagnosis & Treatment Market By Treatment Type (USD Billion, 2025-2035)

Antibiotics
Antivirals
Vaccines
Antifungals

Infectious Disease Diagnosis & Treatment Market By Infectious Disease Type (USD Billion, 2025-2035)

Bacterial Infections
Viral Infections
Fungal Infections
Parasitic Infections

Infectious Disease Diagnosis & Treatment Market By End User (USD Billion, 2025-2035)

Hospitals
Clinical Laboratories
Home Care Settings
Research Institutes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035